Drug Discovery
ByDid Cardiovascular Approvals in 2025 Signal a New Era in Heart Disease Management—and Set the Pace for 2026 Innovation?
Global – December 2025 — The cardiovascular (CV) therapeutic area re-emerged as a strategic growth engine in 2025,…
Did Infectious Disease Approvals in 2025 Redefine Global Preparedness—and Set the Course for Innovation in 2026?
Global – December 2025 — The infectious diseases (ID) landscape underwent a structural recalibration in 2025, shaped by…
Did Neuroscience Approvals in 2025 Mark a Turning Point—and Set the Stage for a Breakout Year in 2026?
Global – December 2025 — The neuroscience sector experienced a long-anticipated resurgence in 2025, driven by regulatory approvals…
Did Immunology Approvals in 2025 Redefine Autoimmune Care—and Set the Stage for a New Growth Cycle in 2026?
Global – December 2025 — The immunology sector entered a decisive transformation in 2025, marked by major regulatory…
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at JPM2026 a Bet on the Next Wave of Immuno-Oncology?
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with a major oncology…
